John, Timothy
Deceased
Timothy John
Demographics
22y, male
Date of death
2013-04-17
Finding date
2017-09-14
Cause of death
Hanging
AI-generated summary
Timothy John, age 22, died by hanging 8 days after commencing varenicline (Champix) for smoking cessation. He had a documented history of depression, anxiety, and substance abuse, with prior attempted suicide. His GP, Dr Y., prescribed Champix without adequately reading product information about neuropsychiatric risks or implementing structured follow-up. Within days, Timothy exhibited escalating psychiatric symptoms (paranoia, aggression, self-harm) that were not communicated to his doctor. The coroner found Champix contributed to his death and that his family should have been informed of warning signs to cease the medication immediately. Key failures included: incomplete risk assessment, no family involvement in monitoring despite available options, inadequate follow-up on a pre-existing mental health condition, and insufficient product labelling accessible to patients.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Error types
Drugs involved
Contributing factors
- Varenicline (Champix) prescribed without adequate risk assessment in patient with psychiatric history
- Inadequate review of product information regarding neuropsychiatric adverse effects
- No structured follow-up plan for patient at higher risk of psychiatric deterioration
- Family not informed of precautions or warning signs requiring cessation of medication
- Inadequate assessment of neuropsychiatric symptoms on follow-up appointment
- Inadequate product labelling accessibility to patients
- Pre-existing major depressive disorder and anxiety disorder
- Prior history of self-harm and suicidal ideation
Coroner's recommendations
- Pfizer Australia and Pfizer Incorporated, in consultation with the TGA, should improve Champix product labelling to include alert about when to immediately cease taking Champix and see a doctor
- Champix Consumer Medicine Information leaflet should be included within the product packaging, not requiring patients to request it from pharmacists or access via Internet
- Clarify guidance in CMI about continuing Champix for 12 weeks versus immediately ceasing if neuropsychiatric symptoms develop
- Product Information document should include practical guidance for medical practitioners on how to alert and advise patients' families about precautions to monitor for neuropsychiatric symptoms, with examples of various clinical scenarios
- Product Information should clarify what constitutes a 'comprehensive counselling and support program' under PBS requirements
- General practitioners should provide direct advice to an appropriate family member, carer, or friend about monitoring for neuropsychiatric symptoms and need to cease Champix immediately if such symptoms develop; if patient refuses, consideration should be given to not prescribing Champix
- All State and Territory forensic pathology services should follow Victoria's lead and conduct routine toxicology screening for Varenicline in relation to suicides and suspected suicides
Full text
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; documents with technically defective redaction have been excluded from the database entirely. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —